Psychedelics as moral bioenhancers: Protocol for a scoping review of ethical arguments for and against
Authors:
- Samuel StreicherSSSamuel Streicher
- Christopher RegisterCRChristopher Register
- Xiu LimXLXiu Lim
- Maide BarışMBMaide Barış
- Sebastian Porsdam MannSMSebastian Porsdam Mann
- Katherine CheungKCKatherine Cheung
- Emma C GordonEGEmma C Gordon
- David YadenDYDavid Yaden
- Julian SavulescuJSJulian Savulescu
- Brian D. EarpBEBrian D. Earp
Open Access
- 13 January 2025
- journal article
- research article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 10
Abstract
Background Moral bioenhancement typically refers to the deliberate use of drugs or biotechnologies, potentially alongside other practices, to attempt to improve oneself morally. In addition to general concerns regarding moral self-bioenhancement, the possibility of using psychedelic substances for such purposes raises distinct ethical questions. As a first step in analysing these questions, we intend to perform a scoping review of the existing arguments for and against the use of psychedelics as moral bioenhancers. We will focus primarily on voluntary use by individuals, although voluntary use by couples or small groups will be considered. The present contribution is a protocol for this scoping review. Methods Our scoping review will adhere to the Joanna Briggs Institute methodology, which involves five stages: (1) identifying the research question, (2) developing the search strategy, (3) setting inclusion criteria, (4) extracting data, and (5) presenting and analysing the results. We will include both published and unpublished sources if they explicitly present ethical arguments for or against the voluntary use of psychedelics as intentional moral bioenhancers in adults. We will search for relevant studies in Embase, MEDLINE, Web of Science, Google Scholar, The National Library of Medicine, the Cumulated Index to Nursing and Allied Health Literature, Philosopher’s Index, the Bioethics Literature Database, EthxWeb, PhilPapers, Stanford Encyclopedia of Philosophy, Philosopher’s Index, EBSCO, BASE, and WorldCat. Sources will be excluded if (a) the full text is inaccessible, (b) the main text is in a language other than English, or (c) the focus is not primarily on ethical arguments (for example, focusing primarily on the clinical use of psychedelics for treatment). Two raters will independently assess all articles for eligibility, with disagreements to be resolved with a third reviewer. Data from eligible articles will be charted using a standardised data extraction form. The data will be analysed following PRISMA-ScR guidelines.Keywords
Funding Information
- Wellcome Trust (226801)
This publication has 67 references indexed in Scilit:
- A Transformative Trip? Experiences of Psychedelic UseNeuroethics, 2024
- Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research LandscapeJAMA Psychiatry, 2023
- Psychedelic Drug Legislative Reform and Legalization in the USJAMA Psychiatry, 2023
- Trust and Psychedelic Moral EnhancementNeuroethics, 2022
- Enhancing GenderJournal of Bioethical Inquiry, 2022
- Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacitiesPsychopharmacology, 2015
- 2C or Not 2C: Phenethylamine Designer Drug ReviewJournal of Medical Toxicology, 2013
- Well‐Being and Enhancement2011
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significancePsychopharmacology, 2006
- The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in miceJournal of Neural Transmission, 1999